Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;5(1):99-102.
doi: 10.1007/s13730-015-0202-1. Epub 2015 Nov 2.

De novo papillary carcinoma in a renal allograft: the pros and cons of immunosuppression

Rachelle Asciak  1 , Jesmar Buttigieg  2 , Louis Buhagiar  2
Affiliations

De novo papillary carcinoma in a renal allograft: the pros and cons of immunosuppression

Rachelle Asciak et al. CEN Case Rep. 2016 May.

Abstract

We present a case of a multifocal kidney transplant renal cell carcinoma in a 35-year-old lady, presenting 16 years after kidney transplantation, diagnosed during investigation of recurrent urinary tract infections. The patient underwent a graft nephrectomy and subsequently maintained on haemodialysis. She remained disease-free after 4 years of surveillance and thus reactivated on the transplant list. This case reinforces the fact that immunosuppressive therapy has made kidney transplantation possible; however, it is accompanied by a higher incidence of malignancy. It also reinforces the importance of lifelong screening of both native and renal transplant grafts.

Keywords: Allograft malignancy; Allograft nephrectomy; Immunosuppression; Kidney transplant.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Ultrasound showing a 1.5 × 1.8 cm homogenously hypo-echoic well-defined isolated nodule in the lower part of the transplanted kidney, with no significant internal blood flow on Doppler evaluation
Fig. 2
Fig. 2
Non-contrast-enhanced CT scan showing the tumour to be well circumscribed to the lower part of the graft
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplants, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725–1730. doi: 10.1056/NEJM199912023412303. - DOI - PubMed
    1. Butler AM, Olshan AF, Kshirsagar AV, et al. Cancer Incidence among US Medicare ESRD patients receiving haemodialysis, 1996–2009. Am J Kidney Dis. 2015; (pii:S0272-6386(15)00017-7). - PMC - PubMed
    1. Arichi N, Kishikawa H, Nishimura K, et al. Malignancy following kidney transplantation. Transplant Proc. 2008;40(7):2400–2402. doi: 10.1016/j.transproceed.2008.07.103. - DOI - PubMed
    1. Stewart JH, Vajdic CM, van Leeuwen MT, et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant. 2009;24(10):3225–3231. doi: 10.1093/ndt/gfp331. - DOI - PubMed
    1. Piselli P, Serraino D, Segoloni GP, et al. Immunosuppression and Cancer Study Group. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009. Eur J Cancer. 2013;49(2):336–344. doi: 10.1016/j.ejca.2012.09.013. - DOI - PubMed

LinkOut - more resources